Clinical trial · Observational
Somatic Mosaicism in Twins Discordant for Childhood Cancer
Somatic Mosaicism in Twins Discordant for Childhood Cancer: a Pilot Study
NCT06054295CI-TRIAL-00098995recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Somatic mosaicism in cancer associated genes is one potential explanation for discordance in childhood cancer that has not been fully explored to date. This pilot study will focus on twins with central nervous system (CNS) tumors who are identified through the Children's Oncology Group's Project: EveryChild (PEC) registry or volunteer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Central Nervous System Tumor | Central Nervous System Neoplasm | ALIAS | 0.90 |
| Discordant Twin | — | UNRESOLVED | — |
| Pediatric Central Nervous System Tumor | Childhood Central Nervous System Neoplasm | ALIAS | 0.90 |
| Somatic Mutation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen collection | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-Correlative
- description
- Twins with CNS tumors, identified through the Children's Oncology Group's Project:EveryChild (PEC) registry, will have both blood and saliva samples collected at the time of study enrollment.
- interventionNames
- Other: Biospecimen collection
- Other: Questionnaire Administration
Primary outcomes (1)
- measure
- Compare the prevalence of somatic mosaicism in classic cancer-associated genes in monozygotic (MZ) twins discordant for childhood brain tumors.
- timeFrame
- Up to 18 months
- description
- Sequence blood and saliva DNA samples from 25 MZ twin pairs using a panel of 94 known cancer associated genes.
Secondary outcomes (1)
- measure
- Compare the profile of mutations detected in DNA extracted from pre- and post-treatment blood samples from a subset of CNS tumor patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed patient with CNS tumor or have recurrent disease and enrolled on APEC14B1. * Patient must have same sex twin. Note: (history of) treatment on a COG therapeutic trial is not required. * Patients must be diagnosed at \< 19 years of age at the time of diagnosis. * A family is eligible to participate if the twin with the CNS tumor is deceased but has a blood sample banked through APEC14B1. * All patients and/or their parents or legal guardians must provide informed consent. Assent will be obtained for participants between the ages of 8-17 years. * All institutional, FDA, and NCI requirements for human studies must be met.
References
Publications (0)
Data not yet available
No reference posted for this study.